Original FTC V. Actavis Case Ends With AbbVie AndroGel Deal

By Dani Kass (February 28, 2019, 8:54 PM EST) -- AbbVie Inc. has agreed not to enter settlements that illegally delay the entry of certain generic drugs, allowing it to avoid a related trial over its testosterone treatment AndroGel slated to start Monday and officially putting an end to the landmark Federal Trade Commission v. Actavis litigation, the agency said Thursday....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!